Over a six-year period.
Interview with CEO Christopher Mattheisen.
Share price drops.
Transactions generate about one-fifth of daily turnover.
Deputy CEO talks acquisition plans.
This would be the biggest Hungarian IPO for a decade.
Key drug to hit shelves in Western Europe soon.
Target price was last raised in March.
Under share option agreements with ING, UniCredit.
Investment banks really start to like OTP.
What will the bank spend it on?
Nearly 20 billion forints worth of dividend will be paid.
The rating agency has recently upgraded FHB's deposit ratings too.
Hungarian fund managers deliver a few surprises.
Challanges all over the place.
Anaemic performance seen in early 2017.